Cardiovascular toxic effects of targeted cancer therapy.

about

Immune checkpoint inhibitor-related myocarditis.Message from the New Editor-in-Chief.In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.

P2860

Q47633085-24CC93B6-854A-4551-8DBE-E781F5866FD5 Q52728758-30333535-9F44-4011-B1F1-1445DEB9CBF4 Q55339567-74E9F44C-7E7E-45F1-9E4D-17EB258DA288

P2860

Cardiovascular toxic effects of targeted cancer therapy.

Item

http://www.wikidata.org/entity/Q53276936

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cardiovascular toxic effects of targeted cancer therapy.

@en

Cardiovascular toxic effects of targeted cancer therapy.

@nl

type

Item

label

Cardiovascular toxic effects of targeted cancer therapy.

@en

Cardiovascular toxic effects of targeted cancer therapy.

@nl

prefLabel

Cardiovascular toxic effects of targeted cancer therapy.

@en

Cardiovascular toxic effects of targeted cancer therapy.

@nl

P1476

Cardiovascular toxic effects of targeted cancer therapy.

@en

P2093

Ikuo Sekine

http://www.w3.org/2001/XMLSchema#string

Kazuko Tajiri

http://www.w3.org/2001/XMLSchema#string

Kazutaka Aonuma

http://www.w3.org/2001/XMLSchema#string

P2860

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

ErbB2 signaling at the crossing between heart failure and cancer

Twenty years of anti-HER2 therapy-associated cardiotoxicity

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

P304

779-785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYX071

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28531278

http://www.w3.org/2001/XMLSchema#string

Cardiovascular toxic effects of targeted cancer therapy.

about

P2860

P2860

Cardiovascular toxic effects of targeted cancer therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698